Iambic's CEO Tom Miller discusses the company's approach to AI drug discovery (hint: it's way more than protein folding), and highlights the company's clinical HER2 program, and two others on the way
- Apr 7
- 1 min read
He describes the multiple variables that factor in to designing new medicines with AI, how Iambic's platform has allowed it to shorten the time to get a medicine into the clinic versus traditional discovery work, and how he thinks AI will augment the work of human scientists.
.png){kind=logo}